Reduction in recurrence of Clostridioides difficile infection (CDI) in patients who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.
Contraind./Precautions⬆⬇
Contraindicated in:
None.
Use Cautiously in:
HF;
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Children <1 yr (safety and effectiveness not established).
Absorption: IV administration results in complete bioavailability.
Distribution: Minimally distributed to tissues.
Metabolism/Excretion: Eliminated primarily through catabolism.
Half-Life: 19 days.
Time/Action Profile⬆⬇
(plasma concentrations)
ROUTE
ONSET
PEAK
DURATION
IV
unknown
unknown
unknown
Patient/Family Teaching⬆⬇
Inform patient that bezlotoxumab does not replace antibacterial treatment for their CDI infection. Antibacterial medications must be continued as directed.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Pronunciation⬆⬇
bez-loe-TOX-ue-mab
Code⬆
NDC Code
0006- Merck Sharp and Dohme Corp.
0006-3025- ZINPLAVA
0006-3025-00- 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-3025-00) > 40 mL in 1 VIAL, SINGLE-DOSE (0006-3025-01)
